FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 329:1659-1660 November 25, 1993 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Ramsey, B. W. PubMed Citation

To the Editor: We are concerned by the conclusion of Ramsey et al. (June 17 issue)¹ that aerosolized tobramycin is not only efficacious but also safe. They state that there was no significant difference with regard to the emergence of tobramycin-resistant bacteria between regimens of aerosolized tobramycin and placebo. During their study tobramycin-resistant Pseudomonas aeruginosa infection developed in 10 of 71 patients (14 percent), P. cepacia in 3 (4 percent), and P. maltophilia (Xanthomonas maltophilia) in 10 (14 percent). Altogether, tobramycin-resistant bacteria developed in 23 of 71 patients (32 percent). If this rate were applied to a population of patients . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.